GUILLERMO GONZALEZ M.D.
Prescription History 1740249986
Internal Medicine - Hematology & Oncology in Tucson, AZ


Quality Rating: 100 out of 100 score

NPI Status: Active since March 17, 2006

Contact Information

3945 E PARADISE FALLS DR STE 105
TUCSON, AZ
ZIP 85712
Phone: (520) 689-7030
Fax: (520) 395-9796

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GUILLERMO GONZALEZ M.D., an active Hematology & Oncology specialist practicing in Tucson, AZ. Our medical registry currently tracks 19 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 655 documented patient claims. Among these therapy options, the most frequently utilized medication is Revlimid, which accounts for 120 claims alone.


Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 100.7
Days Supply 3,020
AZ State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills156.3
Peer Average Days Supply4,670
Conservative Utilization

This provider writes prescriptions for this formulation 46.8% less frequently than the standard regional baseline metric for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,246.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.79

State Avg Cost Per Claim

$26.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Bicalutamide

Generic Formulation: BicalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 91.0
Days Supply 2,720
AZ State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills44.5
Peer Average Days Supply1,313
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,717.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$53.68

State Avg Cost Per Claim

$35.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bicalutamide is used to treat prostate cancer. This medication works by blocking the action of male hormones in the prostate, slowing the growth of cancer cells. This medication should not be used in women and children.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
AZ State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply780
Conservative Utilization

This provider writes prescriptions for this formulation 26.9% less frequently than the standard regional baseline metric for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $269,343.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,175.96

State Avg Cost Per Claim

$15,068.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 55
30-Day Fills 69.0
Days Supply 1,262
AZ State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.7
Peer Average Days Supply405
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 103.7% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $914.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.62

State Avg Cost Per Claim

$16.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Erleada

Generic Formulation: ApalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
AZ State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.0
Peer Average Days Supply629
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $172,019.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,479.12

State Avg Cost Per Claim

$14,611.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Exemestane

Generic Formulation: ExemestaneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 79
30-Day Fills 197.7
Days Supply 5,930
AZ State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills56.4
Peer Average Days Supply1,688
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 216.0% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,797.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$275.91

State Avg Cost Per Claim

$274.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Folic Acid

Generic Formulation: Folic AcidSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 60
30-Day Fills 162.0
Days Supply 4,804
AZ State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills69.0
Peer Average Days Supply2,050
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 114.3% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $322.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.38

State Avg Cost Per Claim

$5.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia.

Therapeutic Applications

Folic acid is the man-made form of folate. Folate is a B-vitamin naturally found in some foods. It is needed to form healthy cells, especially red blood cells. Folic acid supplements may come in different forms (such as L-methylfolate, levomefolate, methyltetrahydrofolate). They are used to treat or prevent low folate levels. Low folate levels can lead to certain types of anemia. Conditions that can cause low folate levels include poor diet, pregnancy, alcoholism, liver disease, certain stomach/intestinal problems, kidney dialysis, among others. Women of childbearing age should receive adequate amounts of folic acid either through their diet or supplements to prevent infant spinal cord birth defects.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.3
Days Supply 572
AZ State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills71.8
Peer Average Days Supply2,134
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $481.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.42

State Avg Cost Per Claim

$46.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
AZ State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.4
Peer Average Days Supply610
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56,555.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,693.12

State Avg Cost Per Claim

$1,425.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.9
Days Supply 826
AZ State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply808
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $229,247.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,490.64

State Avg Cost Per Claim

$14,703.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
AZ State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.1
Peer Average Days Supply508
Conservative Utilization

This provider writes prescriptions for this formulation 26.3% less frequently than the standard regional baseline metric for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $144,301.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,307.26

State Avg Cost Per Claim

$12,737.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 45.3
Days Supply 1,341
AZ State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills162.7
Peer Average Days Supply4,863
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.7% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $334.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.93

State Avg Cost Per Claim

$29.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
AZ State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.3
Peer Average Days Supply517
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $194,869.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,826.07

State Avg Cost Per Claim

$12,962.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 310
AZ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply215
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.3% more claims than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $436.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.58

State Avg Cost Per Claim

$18.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
AZ State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.2
Peer Average Days Supply516
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $107,693.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,179.54

State Avg Cost Per Claim

$14,052.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Revlimid

Generic Formulation: LenalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 120
30-Day Fills 120.0
Days Supply 3,360
AZ State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills43.6
Peer Average Days Supply1,185
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 179.1% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,118,585.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,654.88

State Avg Cost Per Claim

$18,290.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 42.0
Days Supply 1,260
AZ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills75.3
Peer Average Days Supply2,249
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.3% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $617.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.12

State Avg Cost Per Claim

$38.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 830
AZ State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.3
Peer Average Days Supply484
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 70.6% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $251,848.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,684.43

State Avg Cost Per Claim

$13,848.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
AZ State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply787
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 26.9% more claims than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $409,254.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,401.65

State Avg Cost Per Claim

$13,042.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GUILLERMO GONZALEZ M.D. provides transparency into local medical care patterns within Tucson, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.